Jefferies Group LLC Argenx Se Transaction History

Jefferies Group LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$248.13 - $308.36 $1.18 Million - $1.46 Million	-4,750 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$215.51 - $272.51 $4.15 Million - $5.25 Million	-19,250 Reduced 80.21%	4,750 $1.25 Million
Q2 2020 Aug 14, 2020	BUY	$127.44 - $232.72 $3.06 Million - $5.59 Million	24,000 New	24,000 $5.41 Million
Q4 2019 Feb 13, 2020	SELL	$106.59 - $164.21 $598,076 - $921,382	-5,611 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$113.31 - $150.51 $635,782 - $844,511	5,611 New	5,611 $639,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.